Hajnalka E. Davis - Concepedia

Author

Hajnalka E. Davis

Also Known As

Hajnalka Davis, Hajnalka E. Davis

Publications

166

Citations

H-Index

Concepts

All Affiliations

Hajnalka E. Davis is an author at AstraZeneca (United States) specializing in medicine, natural sciences, and microbiology.

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	166
2	Natural Sciences	4	4	166
3	Microbiology	4	4	166
4	Biochemistry	3	3	154
5	Chemical Biology	1	1	27

Hajnalka E. Davis

Publications

166

Citations

H-Index

Page 1

	Year	Citations
Novel N-Linked Aminopiperidine Inhibitors of Bacterial Topoisomerase Type II: Broad-Spectrum Antibacterial Agents with Reduced hERG Activity Folkert Reck, Richard A. Alm, Patrick Brassil, Journal of Medicinal Chemistry Reduced Herg ActivityAntimicrobial ChemotherapyPharmaceutical ChemistryDrug ResistanceMedicinal Chemistry	2011	101
SAR and Structural Analysis of Siderophore-Conjugated Monocarbam Inhibitors of <i>Pseudomonas aeruginosa</i> PBP3 Kerry E. Murphy-Benenato, Brian Dangel, Hajnalka E. Davis, ACS Medicinal Chemistry Letters New AgentsTarget PenicillinAntimicrobial ChemotherapyAnalytical UltracentrifugationChemical Biology	2015	27
Discovery of Efficacious <i>Pseudomonas aeruginosa</i>-Targeted Siderophore-Conjugated Monocarbams by Application of a Semi-mechanistic Pharmacokinetic/Pharmacodynamic Model Kerry E. Murphy-Benenato, Pratik Bhagunde, April Chen, Journal of Medicinal Chemistry Lead CompoundsNew AgentsAntimicrobial ChemotherapyPharmacodynamic ModelingDrug Resistance	2015	26
Identification through structure-based methods of a bacterial NAD+-dependent DNA ligase inhibitor that avoids known resistance mutations Kerry E. Murphy-Benenato, Hongming Wang, Helen M. McGuire, Bioorganic & Medicinal Chemistry Letters Antimicrobial Resistance GeneStructural BioinformaticsNatural SciencesStructure-based MethodsDna Replication	2013	12

Page 1